Ocugen (OCGN) Amortization of Deferred Charges (2014 - 2026)
Ocugen's (OCGN) quarterly Amortization of Deferred Charges came in at $25000.0 in Q1 2026, down 91.67% YoY from $300000.0 in Q1 2025, and little changed on a QoQ basis from $25000.0 in Q4 2025.
Analysis
Ocugen (OCGN) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 10 years of Amortization of Deferred Charges data on file, last reported at $25000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges fell 91.67% year-over-year to $25000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$175000.0 (down 160.98% YoY) and the FY2025 annual result came in at $100000.0, up 525.0% from the prior year.
- Amortization of Deferred Charges steadied at $25000.0 in Q1 2026, from $25000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $300000.0 in Q1 2025 to a low of -$250000.0 in Q2 2025.
- A 5-year average of $20000.0 and a median of $25000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 934.48% in 2025, down 992.86% in 2025.
- Tracing OCGN's Amortization of Deferred Charges over 5 years: stood at $25000.0 in 2022, then gained by 16.0% to $29000.0 in 2023, then plunged by 344.83% to -$71000.0 in 2024, then jumped by 135.21% to $25000.0 in 2025, then changed by 0.0% to $25000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $25000.0 (Q1 2026), $25000.0 (Q4 2025), and $25000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Dec 31, 2014 | 77,000.00 |
| Sep 30, 2014 | 79,000.00 |
| Jun 30, 2014 | -80,000.00 |
| Mar 31, 2014 | -38,000.00 |